Ashfield creates cell and gene therapy commercialization network


EmerGENE to support biotechs in clinical-to-commercialization process, including distribution and logistics

Ashfield, part of UDG Healthcare plc, has launched EmerGENE, a global end-to-end cell and gene therapy network that is intended to support small and midsize biotechs with the commercialization of their drug discoveries.

Specifically, the new system offers guidance and services to biotechs as they navigate their clinical-to-commercial journey, including commercialization strategic support, distribution and logistics and market access, among other areas.

Combining experts from Ashfield Health, Ashfield Engage and Ashfield Advisory, which were formed in late January, EmerGENE aims to unlock the potential of cell and gene therapy, helping drug developers to bring transformational treatments to patients.

“At Ashfield, we look to embed ourselves into our customers’ businesses and use our expertise to create tangible solutions which best meet their needs,” says Amar Urhekar, global president, Ashfield Health. “EmerGENE is no different, and with over 1,200 cell and gene therapy clinical trials currently underway globally, and 1,000 different manufacturers exploring cell and gene therapies right now, it’s clear that there is demand for support in this space.“

Related Videos
© 2024 MJH Life Sciences

All rights reserved.